# AstraZeneca’s Orpathys approved in China for patients with lung cancer

- Link: https://www.directorstalkinterviews.com/astrazenecas-orpathys-approved-in-china-for-patients-with-lung-cancer/4121003389
- Published: 2021-06-23T07:25:04+01:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
and HUTCHMED’s _Orpathys_ (savolitinib) has been granted conditional approval in
China to treat patients with non-small cell lung cancer (NSCLC) with MET exon 14
skipping alterations who have progressed following prior systemic therapy or are
unable to receive chemotherapy.

This approval follows a priority review designation by the Center for Drug Evaluation
of China’s National Medical Products Administration (NMPA) and marks the first global
regulatory approval for the oral, potent, and highly selective MET tyrosine kinase
inhibitor (TKI).

More than a third of the world’s lung cancer patients are in China and, among those
with NSCLC, approximately 2-3% have tumours with MET exon 14 skipping alterations,
a targetable mutation in the MET gene.^(1-3) This mutation is more common (13-22%)
among patients with pulmonary sarcomatoid carcinoma (PSC), a rare and aggressive
subtype of NSCLC usually resistant to chemotherapy.^(1,4)

The approval by the NMPA was based on positive results from a single-arm Phase II
trial conducted in China in patients with NSCLC with this mutation, including patients
with the PSC subtype. _Orpathys_ demonstrated robust anti-tumour activity based 
on an independent review of objective response rate (ORR) in the trial’s primary
endpoint and its disease control rate (DCR). Continued approval is contingent upon
the successful completion of a confirmatory trial in this patient population.

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit, said**: “
> This approval makes _Orpathys_ the only targeted medicine approved for these biomarker-
> selected patients in China, and it adds another novel medicine to our already 
> diverse lung cancer portfolio. We are proud that this first-ever regulatory approval
> of _Orpathys_ is in China, where we have a long-standing commitment to improving
> patient outcomes and working with the right partners to achieve that goal. Alongside
> HUTCHMED, we look forward to the continued development of this medicine across
> a range of cancers where MET alterations and amplification are drivers of tumour
> growth and treatment resistance.”

> **Christian Hogg, Chief Executive Officer, HUTCHMED, said**: “It is with great
> pleasure that today we announce the first regulatory approval of _Orpathys_ globally,
> HUTCHMED’s third self-discovered oncology drug to be commercialized. Our collaboration
> with AstraZeneca in 2011 has been an important driver in the development of this
> novel targeted oncology drug, involving both a China-based biotech and a global
> pharmaceutical company. This approval is a testament to the perseverance and scientific
> ingenuity of this long-standing alliance, and we are hopeful that this is only
> the beginning of the progress we can achieve for patients with MET-altered tumours.”

In the Phase II trial, at a median follow up of 17.6 months, _Orpathys_ demonstrated
an ORR of 42.9% (95% confidence interval [CI] 31.1-55.3) and median progression-
free survival (PFS) of 6.8 months (95% CI 4.2-9.6) in the overall trial population.
PFS was clinically meaningful across subgroups, and ORR results were consistent 
regardless of prior treatment or tumour histology, including in patients with the
PSC subtype (40.0%, 95% CI 21.1-61.3) and patients with other NSCLC subtypes (44.4%,
95% CI 29.6-60.0). DCR in the overall trial population was 82.9% (95% CI 72.0-90.8).

The safety and tolerability profile of _Orpathys_ was consistent with previous trials,
and no new safety signals were identified. Most adverse events (AEs) were Grade 
1-2 and resolved with dose modification or discontinuation. Grade 3 or higher AEs
occurred in 45.7% of patients, and treatment-related serious AEs occurred in 24%
of patients. One treatment-related death was reported from tumour lysis syndrome
in a patient with PSC.

Results from the Phase II trial were presented during the American Society of Clinical
Oncology ASCO20 Virtual Scientific Program in May 2020, and updated results were
published in The Lancet Respiratory Medicine in June 2021.

As part of the joint global development programme with HUTCHMED, _Orpathys_ is being
evaluated in combination with _Tagrisso_ and other medicines to address tumour mechanisms
of resistance in NSCLC in the ORCHARD and SAVANNAH Phase II trials for the combinations
to provide longer duration of benefit, and as a treatment for other MET-driven tumours,
including papillary renal cell carcinoma, and gastric and gastroesophageal junction
cancers.

**NSCLC, PSC and MET aberrations**

Lung cancer is the leading cause of cancer death among men and women, accounting
for about one-fifth of all cancer deaths.^(2) Lung cancer is broadly split into 
NSCLC and small cell lung cancer, with 80-85% classified as NSCLC.^(5 )The majority
of NSCLC patients are diagnosed with advanced disease.^(6)

PSC is a rare subtype of NSCLC, comprising 0.3-3% of all lung malignancies.^(7) 
Compared with other NSCLC subtypes, PSC patients have a poorer prognosis and limited
treatment options.^(4,8-9)

MET is a tyrosine kinase receptor.^(10) While MET genetic alterations are common
in many solid tumours, MET exon 14 skipping alterations are more frequently associated
with lung cancer, occurring in approximately 2-3% of patients with NSCLC and 13-
22% of patients with PSC.^(1,4,11) MET amplification or overexpression is one of
the mechanisms of acquired resistance to epidermal growth factor receptor (EGFR)
TKIs for metastatic EGFR-mutated NSCLC.^(10)

**NCT02897479**

The single-arm, open-label Phase II trial NCT02897479 assessed the efficacy and 
safety of _Orpathys_ in the treatment of Chinese patients with locally advanced 
or metastatic PSC or other NSCLC subtypes with MET exon 14 skipping alterations 
who progressed on prior treatment or were unable to receive chemotherapy.

Patients were treated with weight-based dosing of _Orpathys_ once-daily oral tablets(
600mg/day or 400mg/day for patients weighing less than 50kg). Treatment continued
until disease progression, death, intolerable toxicity, or discontinuation. The 
trial enrolled 70 patients across multiple centres in China. The primary endpoint
was ORR, and key secondary endpoints were PFS, DCR and safety assessment.

**Orpathys**

_Orpathys_ (savolitinib) is an oral, potent, and highly selective MET TKI that has
demonstrated clinical activity in advanced solid tumours. It blocks atypical activation
of the MET receptor tyrosine kinase pathway that occurs because of mutations (such
as exon 14 skipping alterations or other point mutations) or gene amplification.

_Orpathys _is currently under clinical development for multiple tumour types, including
lung, kidney, and gastric cancers, as a single treatment and in combination with
other medicines.

**AstraZeneca and HUTCHMED collaboration**

In 2011, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly
develop and commercialise _Orpathys_. HUTCHMED is responsible for the manufacturing
and supply of _Orpathys_, and AstraZeneca is responsible for its commercialisation
in China and worldwide. Sales of _Orpathys_ will be recognised by AstraZeneca.

Share on:
